MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
22.74
-2.06
-8.30%
Opening 09:44 03/30 EDT
OPEN
24.00
PREV CLOSE
24.80
HIGH
24.20
LOW
22.52
VOLUME
294.99K
TURNOVER
--
52 WEEK HIGH
30.60
52 WEEK LOW
2.760
MARKET CAP
2.89B
P/E (TTM)
-7.9467
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST)
TipRanks · 3h ago
ALUMIS INC. <ALMS.O>: OPPENHEIMER RAISES TARGET PRICE TO $55 FROM $50
Reuters · 3h ago
Alumis Is Maintained at Buy by Chardan Capital
Dow Jones · 3h ago
Alumis Price Target Maintained With a $38.00/Share by Chardan Capital
Dow Jones · 3h ago
Alumis price target raised to $55 from $50 at Oppenheimer
TipRanks · 4h ago
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Alumis Inc. (ALMS) and Boston Scientific (BSX)
TipRanks · 4h ago
Analysts Are Bullish on These Healthcare Stocks: Disc Medicine (IRON), Alumis Inc. (ALMS)
TipRanks · 4h ago
Alumis Price Target Cut to $25.00/Share From $40.00 by HC Wainwright & Co.
Dow Jones · 5h ago
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.